Core Viewpoint - Inke Medical announced a significant investment of $70 million (approximately 500 million RMB) in Warburg Pincus Global Growth 15, L.P., aiming to enhance capital efficiency and financial returns while promoting deep integration of capital and industry [1][3]. Investment Details - The partnership fund has a target fundraising size of $17 billion, with Inke Medical participating as a limited partner (LP) [1][3]. - The fund's investment focus includes healthcare, energy transition, business services, industrial, technology, consumer sectors, and sustainable development [3]. Financial Performance - In the first half of 2025, Inke Medical reported revenue of 4.913 billion RMB, an increase of 8.9% year-on-year [3]. - The net profit attributable to shareholders was 710 million RMB, reflecting a year-on-year growth of 21.02% [3]. - The net cash flow from operating activities reached 745 million RMB, a significant increase of 170.15% compared to the same period last year [3]. - As of June 30, 2025, the total assets amounted to 39.515 billion RMB, up 14.10% from the end of the previous year [3]. - The cash and cash equivalents balance was 11.738 billion RMB, with trading financial assets totaling 10.857 billion RMB, bringing the combined total to 22.595 billion RMB [3]. Company Overview - Inke Medical Technology Co., Ltd. is a high-tech manufacturing enterprise focused on the research, production, and marketing of medical device consumables [3]. - The company was listed on the Shenzhen Stock Exchange's Growth Enterprise Market in July 2017 and offers a range of products including medical consumables, health care devices, and therapeutic care products [3].